BCL2 and plasma cell myeloma: ABT-737 binds Bcl-2 and Bcl-xL with high affinity and has shown single agent and combination therapy efficacy against multiple myeloma, acute myeloid leukaemia, lymphoma and solid tumour cell lines 21.